Optimize Surveillance with Sensitive, Standardized Analytical Assays, Clinically Validated MRD Tests & Reliable ctDNA Surrogate Biomarkers to Detect Disease Earlier & Improve Patient Outcomes

November 7-9, 2023 | Boston, MA

Welcome to the 2nd Liquid Biopsy Surveillance & Early Detection Summit

Accelerating Patient Access to Early & Affordable Detection & Surveillance Tests

The 2nd Liquid Biopsy Surveillance & Early Detection Summit returns as industry’s only meeting showcasing biopharma-led case studies and assay developer technical progress to create a commercially viable path forward for non-invasive testing to support early disease pipeline progress.

Ensure your whole team stays connected and ahead of the curve with unmatched industry insights across key challenges in scaling sensitive assays that enable earlier detection and utilizing ctDNA as a surrogate biomarker to improve surveillance for a paradigm shift towards achieving personalized treatment options.

Uniting patients, diagnostics and drug developers, this meeting is your one and only opportunity to learn about the latest advancements in liquid biopsy detection and early surveillance in oncology, neurology and rare disease, and how they can be implemented into clinical trials and in healthy populations.

2022 Speaker Faculty Included

Aleksandra Markovets



Amanda Acerbi

Precision Medicine Global Director


Cecília Schott

VP, Global Head Precision Dx

Novartis AG

Feng Liu



Gary Kelloff

Special Advisor, DCTD, National Cancer Institute


Lauren Leiman

Executive Director


Minakshi Guha

LBx Strategy Lead, Companion Diagnostics

Takeda Pharmaceutical Co. Ltd.

Raluca Budiu-Predoiu

Director, Precision Medicine


Our 2023 Partners

Hear What Experts 2022 Attendees Had to Say…

“The event offered a great opportunity to network and promote my company and its services to advance the study in cancer treatment”

Translational Medicine Scientist, Burning Rock Biotech

“I really enjoyed the fact that we had the first LBx-focused summit here in the Boston area. I enjoyed networking with my fellow ex-colleagues, partners and collaborators”

LBx Strategy Lead, Precision Medicine & CDx, Takeda

“I enjoyed discussing the emerging clinical data and pathways towards clinical implantation for patient benefit”

WW Medical Lead, Bristol Myers Squibb

View the 2023 Full Event Guide Now!


Download your copy to find the 2023 speakers, full agenda breakdown, partners, accessing the best possible rates and to see how biopharma & academia can *secure their FREE pass

Other Events in the Series